期刊
ONCOLOGIST
卷 12, 期 12, 页码 1425-1432出版社
WILEY
DOI: 10.1634/theoncologist.12-12-1425
关键词
hepatocellular carcinoma; liver neoplasms; chemoembolization; drug therapy; doxorubicin; sorafenib; bevacizumab; erlotinib
类别
资金
- NATIONAL CANCER INSTITUTE [K23CA118431] Funding Source: NIH RePORTER
- NCI NIH HHS [5 K23 CA118431-02] Funding Source: Medline
Hepatocellular carcinoma (HCC) is a disease that requires multidisciplinary management. There has been no widely accepted standard for systemic therapy for this disease until recently. This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据